Klinische Wochenschrift

, Volume 59, Issue 24, pp 1323–1332 | Cite as

Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own erythrocytes during glycoside therapy

  • J. K. Aronson
  • A. R. Ford
  • D. G. Grahame-Smith


We have measured the effects of digoxin on the cation transport mechanisms of patients' erythrocytes during treatment with digoxin for atrial fibrillation and cardiac failure in sinus rhythm. The results show that during short-term treatment with digoxin there is occupation of erythrocytic cardiac glycoside receptors by digoxin with resultant inhibition of active cation transport. These effects correlate well with the patients' clinical responses to treatment. During long-term treatment, however, these effects are not seen, suggesting that there is pharmacological tolerance to the effects of digoxin. The clinical implications of these results are discussed.

Key words

Cardiac glycosides Cation transport 

Verfahren zur Untersuchung pharmakodynamischer Effekte von Herzglykosiden an Patientengewebe während Glykosidtherapie


Die Effekte von Digoxin auf die Mechanismen des Kationentransportes wurden an den Erythrozyten der Patienten untersucht. Die Studien wurden während Digoxinbehandlung bei Vorhofflimmern und bei Herzinsuffizienz mit Sinusrhythmus durchgeführt. Die Resultate zeigen, daß während kurzzeitiger Behandlung mit Digoxin die Rezeptoren für Herzglykoside an den Erythrozyten besetzt werden, woraus eine Hemmung des aktiven Kationentransportes resultiert. Diese Wirkungen zeigen eine gute Korrelation mit dem klinischen Erfolg der Behandlung. Während Langzeitbehandlung lassen sich diese Wirkungen jedoch nicht nachweisen. Dieser Befund legt nahe, daß dabei eine pharmakologische Toleranz gegenüber den Digoxinwirkungen eintritt. Die klinische Bedeutung dieser Befunde wird diskutiert.


Herzglykoside Kationentransport 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aronson JK (1975) The application of digoxin radioimmunoassay in monitoring drug therapy. In: Pasternak C (ed) Radioimmunoassay in clinical biochemistry. Heyden, London New York RheineGoogle Scholar
  2. 2.
    Aronson JK, Grahame-Smith DG, Hallis KF, Hibble AG, Wigley FM (1977) Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol 4:213–221Google Scholar
  3. 3.
    Aronson JK, Grahame-Smith DG, Wigley FM (1978) Monitoring digoxin therapy: the use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. Q J Med 47:111–121Google Scholar
  4. 4.
    Aronson JK (1980) Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG (ed) Meyler's side effects of drugs, Annual 4. Excerpta Medica, AmsterdamGoogle Scholar
  5. 5.
    Aronson JK, Ford AR (1980) The use of colour vision measurement in the diagnosis of digoxin toxicity. Q J Med 49:273–282Google Scholar
  6. 6.
    Erdman E, Hasse W (1975) Quantitative aspects of ouabain binding to human erythrocyte and cardiac membranes. J Physiol (Lond) 251:671–682Google Scholar
  7. 7.
    Ford AR, Aronson JK, Grahame-Smith DG, Rose JA (1979) The characteristics of the binding of 12-α-3H-digoxin to the membranes of intact human erythrocytes. Br J Clin Pharmacol 8:115–124Google Scholar
  8. 8.
    Ford AR, Aronson JK, Grahame-Smith DG, Carver JG (1979) Changes in cardiac glycoside receptor sites,86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol 8:125–134Google Scholar
  9. 9.
    Ford AR, Aronson JK, Grahame-Smith DG, Carver JG (1979) The acute changes seen in cardiac glycoside receptor sites,86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy. Br J Clin Pharmacol 8:135–142Google Scholar
  10. 10.
    Ingelfinger J, Goldman P (1976) The serum digitalis concentration — does it diagnose digitalis toxicity? N Engl J Med 294:867–899Google Scholar
  11. 11.
    Schwartz A, Lindenmeyer GE, Allen JC (1975) The sodium-potassium, adenosine triphosphatase: pharmacological, physiological and biochemical aspects. Pharmac Rev 27:3–34Google Scholar
  12. 12.
    Weissler AM, Lewis RP, Leighton RF (1972) The systolic time intervals as a measure of left ventricular performance in man. In: Yu PN, Goodwin JF (eds) Progress in cardiology. Lea & Febiger, PhiladelphiaGoogle Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • J. K. Aronson
    • 1
  • A. R. Ford
    • 1
  • D. G. Grahame-Smith
    • 1
  1. 1.MRC Clinical Pharmacology UnitUniv. Dept. of Clinical Pharmacology Radcliffe InfirmaryOxfordEngland

Personalised recommendations